Stay updated on SAGE-217 for Severe Postpartum Depression Clinical Trial

Sign up to get notified when there's something new on the SAGE-217 for Severe Postpartum Depression Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SAGE-217 for Severe Postpartum Depression Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:33:51.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy and safety evaluation of SAGE-217 in treating severe postpartum depression compared to a placebo in female participants.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:59.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying that participants must have ceased lactating and meet certain health conditions related to postpartum depression. Previously, no information was provided about the participation criteria.
    Difference
    12%
    Check dated 2024-05-22T21:37:27.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:53:29.000Z thumbnail image

Stay in the know with updates to SAGE-217 for Severe Postpartum Depression Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SAGE-217 for Severe Postpartum Depression Clinical Trial page.